“…Among them, TNBC is clinically de ned as BC with negative ER, PR, and HER-2, which is the most aggressive and heterogeneous subtype, and there are about 200000 new cases every year, accounting for 15-20% of the total cases and 25% of all BC related deaths(Yin, Jiang, Xu, Jia, & Lin, 2023; Zhao et al, 2023). Moreover, its recurrence rate is high, the metastasis ability is strong, the prognosis is poor, and the survival rate is low (Beniey et al, 2023;Chu et al, 2023;Huang et al, 2023). A large number of researches show that TNBC is an invasive disease characterized by drug resistance and distant metastasis(Lawal, Wu, Chen, T, & .…”